urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2021-9-2-150-156urovest-445Research ArticleОБМЕН ПРАКТИЧЕСКИМ ОПЫТОМEXCHANGE OF PRACTICAL EXPERIENCEБолезнь Пейрони и первый опыт использования Пейрофлекса®Peyronie's disease and the first user experience of Peyroflex®https://orcid.org/0000-0002-0808-2560ШиринГ. В.ShirinG. V.

Ширин Геннадий Владимирович —заведующий отделением урологии КДЦ Медси на Белорусской

123056, Москва, Грузинский переулок, д. 3а.

Тел.: +7 (903) 139-50-27

Gennadiy V. Shirin — M.D.; Head, Urology Division, «Medsi» Corporate Group.

123056, Moscow, 3a Gruzinsky ln.

Tel.: +7 (903) 139-50-27

genofond@list.ruhttps://orcid.org/0000-0002-1265-7187ФедороваН. А.FedorovaN. A.

Федорова Наталия Александровна — кандидат медицинских наук, врач ультразвуковой диагностики ООО «АмирМед».

143405, Красногорск, Ильинское шоссе, а/ост. «Бецема».

Nataliya A. Fedorova — M.D., Cand.Sc. (M); Ultrasound Diagnostics Physician, «AmirMed» Ltd.

143405, Krasnogorsk, Ilyinskoe hwy, bus stop - «Betsema».

nataliya-f@mail.ruАО «Группа компаний «Медси»Россия«Medsi» Corporate GroupRussian FederationООО «АмирМед»Россия«AmirMed» Ltd.Russian Federation20210807202192150156Copyright © Ширин Г.В., Федорова Н.А., 20212021Ширин Г.В., Федорова Н.А.Shirin G.V., Fedorova N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/445

В статье рассмотрены современные вопросы этиологии, патогенеза и клинического течения болезни Пейрони. Продемонстрированы диагностические возможности использования ультразвукового метода исследования. Произведён обзор международных данных об известных вариантах лечения болезни Пейрони. Описан собственный опыт применения препарата Пейрофлекс® на ранней стадии заболевания и дана предварительная оценка его эффективности.

The article deals with the current issues of the etiology, pathogenesis and clinical course of Peyronie's disease. The diagnostic possibilities of using ultrasound sonography are demonstrated. The international data on known treatment options for Peyronie's disease are reviewed. The author describes his own user experience of the Peyroflex® at an early stage of the disease and gives a preliminary assessment of its effectiveness.

болезнь Пейронифиброзные бляшкидиагностикалечениеПейрофлекс®Peyronie's diseasefibrous plaquesdiagnosticstreatmentPeyroflex®ReferencesLaRochelle JC, Levine LA. A Survey of primary-care physicians and urologists regarding Peyronie's disease. J Sex Med. 2007;4(4 Pt 2):1167-73. DOI: 10.1111/j.1743-6109.2007.00537.xLaRochelle JC, Levine LA. A Survey of primary-care physicians and urologists regarding Peyronie's disease. J Sex Med. 2007;4(4 Pt 2):1167-73. DOI: 10.1111/j.1743-6109.2007.00537.xChung PH, Han TM, Rudnik B, Das AK. Peyronie's disease: what do we know and how do we treat it? Can J Urol. 2020;27(S3):11-19. PMID: 32875997.Chung PH, Han TM, Rudnik B, Das AK. Peyronie's disease: what do we know and how do we treat it? Can J Urol. 2020;27(S3):11-19. PMID: 32875997.Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006;175(6):2115-8; discussion 2118. DOI: 10.1016/S0022-5347(06)00270-9Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006;175(6):2115-8; discussion 2118. DOI: 10.1016/S0022-5347(06)00270-9Kalokairinou K, Konstantinidis C, Domazou M, Kalogeropoulos T, Kosmidis P, Gekas A. US Imaging in Peyronie's Disease. J Clin Imaging Sci. 2012;2:63. DOI: 10.4103/2156-7514.103053Kalokairinou K, Konstantinidis C, Domazou M, Kalogeropoulos T, Kosmidis P, Gekas A. US Imaging in Peyronie's Disease. J Clin Imaging Sci. 2012;2:63. DOI: 10.4103/2156-7514.103053Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU-Guidelines Male sexual dysfunction. European Association of Urology, 2019.Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU-Guidelines Male sexual dysfunction. European Association of Urology, 2019.Hauptmann A, Wagenlehner FME, Diemer T. Aktuelle Therapie der Induratio penis plastica (IPP). Urologe. 2018;57:1139-1152. DOI: 10.1007/s00120-018-0752-xHauptmann A, Wagenlehner FME, Diemer T. Aktuelle Therapie der Induratio penis plastica (IPP). Urologe. 2018;57:1139-1152. DOI: 10.1007/s00120-018-0752-xHatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, Vardi Y, Wespes E; European Association of Urology. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543-52. DOI: 10.1016/j.eururo.2012.05.040Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, Vardi Y, Wespes E; European Association of Urology. EAU guidelines on penile curvature. Eur Urol. 2012;62(3):543-52. DOI: 10.1016/j.eururo.2012.05.040Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies. Inflamm Allergy Drug Targets. 2012;11(1):48-57. DOI: 10.2174/187152812798889321Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies. Inflamm Allergy Drug Targets. 2012;11(1):48-57. DOI: 10.2174/187152812798889321Lopez JA, Jarow JP. Penile vascular evaluation of men with Peyronie's disease. J Urol. 1993;149(1):53-5. DOI: 10.1016/s0022-5347(17)35997-9Lopez JA, Jarow JP. Penile vascular evaluation of men with Peyronie's disease. J Urol. 1993;149(1):53-5. DOI: 10.1016/ s0022-5347(17)35997-9Chung E, Yan H, De Young L, Brock GB. Penile Doppler sonographic and clinical characteristics in Peyronie's disease and/or erectile dysfunction: an analysis of 1500 men with male sexual dysfunction. BJU Int. 2012;110(8):1201-5. DOI: 10.1111/j.1464-410X.2011.10851.xChung E, Yan H, De Young L, Brock GB. Penile Doppler sonographic and clinical characteristics in Peyronie's disease and/or erectile dysfunction: an analysis of 1500 men with male sexual dysfunction. BJU Int. 2012;110(8):1201-5. DOI: 10.1111/j.1464-410X.2011.10851.xLevine L, Rybak J, Corder C, Farrel MR. Peyronie's disease plaque calcification--prevalence, time to identification, and development of a new grading classification. J Sex Med. 2013;10(12):3121-8. DOI: 10.1111/jsm.12334Levine L, Rybak J, Corder C, Farrel MR. Peyronie's disease plaque calcification--prevalence, time to identification, and development of a new grading classification. J Sex Med. 2013;10(12):3121-8. DOI: 10.1111/jsm.12334Мазо Е.Б., Зубарев А.Р., Жуков О.Б. Ультразвуковая диагностика васкулогенной эректильной дисфункции. М.: Медицина; 2003.Maso E. B., Zubarev A. R., Zhukov O. B. Ultrasound diagnostics of vasculogenic erectile dysfunction. M.: Medicine; 2003. (In Russ.).Porst H, Burri A; European Society for Sexual Medicine (ESSM) Educational Committee. Current Strategies in the Management of Peyronie's Disease (PD)-Results of a Survey of 401 Sexual Medicine Experts Across Europe. J Sex Med. 2019;16(6):901-908. DOI: 10.1016/j.jsxm.2019.03.404. Erratum in: J Sex Med. 2019;16(9):1486Porst H, Burri A; European Society for Sexual Medicine (ESSM) Educational Committee. Current Strategies in the Management of Peyronie's Disease (PD)-Results of a Survey of 401 Sexual Medicine Experts Across Europe. J Sex Med. 2019;16(6):901-908. DOI: 10.1016/j.jsxm.2019.03.404. Erratum in: J Sex Med. 2019;16(9):1486Pryor JP, Farell CR. Controlled clinical trial of vitamin E in Peyronie's disease. Prog. Reprod. Biol. Med. 1983;9:41-45Pryor JP, Farell CR. Controlled clinical trial of vitamin E in Peyronie's disease. Prog. Reprod. Biol. Med. 1983;9:41-45Halal AA, Geavlete P, Ceban E. Pharmacological therapy in patients diagnosed with Peyronie's disease. J Med Life. 2012;5(2):192-5. PMID: 22802890; PMCID: PMC3391879Halal AA, Geavlete P, Ceban E. Pharmacological therapy in patients diagnosed with Peyronie's disease. J Med Life. 2012;5(2):192-5. PMID: 22802890; PMCID: PMC3391879Paulis G, Brancato T, D'Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, Alvaro R. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120-8. DOI: 10.1111/j.2047-2927.2012.00007.xPaulis G, Brancato T, D'Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, Alvaro R. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120-8. DOI: 10.1111/j.2047-2927.2012.00007.xShah P, Green N, Adib R. A multicentre double blind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie's disease. Prog Reprod Biol Med. 1983;9:61-67Shah P, Green N, Adib R. A multicentre double blind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie's disease. Prog Reprod Biol Med. 1983;9:61-67Weidner W, Hauck EW, Schnitker J; Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-5; discussion 535-6. DOI: 10.1016/j.eururo.2004.12.022Weidner W, Hauck EW, Schnitker J; Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-5; discussion 535-6. DOI: 10.1016/j.eururo.2004.12.022Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88(1):63-7. DOI: 10.1046/j.1464-410x.2001.02241.xBiagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88(1):63-7. DOI: 10.1046/j.1464-410x.2001.02241.xCavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 2002;89(9):895-900. DOI: 10.1046/j.1464-410x.2002.02738.xCavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 2002;89(9):895-900. DOI: 10.1046/j.1464-410x.2002.02738.x

The authors declare that there are no conflicts of interest present.